Zedira has received further funding from the German Federal Ministry for Education and Research (German abbreviation: BMBF). The project volume has been extended by € 1.0 Mio. so that the total project value exceeds € 5.0 Mio. by now. The additional funding will allow completing the development of a drug candidate for „safe“ anticoagulation.
Zedira targets coagulation factor XIIIa (F13, plasma transglutaminase) using direct acting peptidomimetic inhibitors including proof – of – concept studies in relevant animal models. Further, Zedira continues the successful cooperation in the field of structural biology with the group of Prof. Gerhard Klebe, Marburg University.
Dr. Martin Hils, managing partner, comments: „ We are more than happy to receive funding for this cutting – edge project within this highly competitive program. The grant is a special ho nor underlining our successful drug discovery approach over the past decade.
Dr. Ralf Pasternack, managing partner, adds: „After licensing our lead project in the field of celiac disease to Dr. Falk Pharma, the FXIII – project further strengthens our leadin g international position in the transglutaminase field. We are confident that our approach, due to the unique mode – of – action, will p rovide a safer therapeutic opportunity in anticoagulation for patients, doctors and payers. _________________________________________________________________
This press release is from : Zedira GmbH Roesslerstr. 83 64293 Darmstadt Germany Phone: +49 6151 3251 – 00 Fax: +49 6151 3251 – 19 Web: www.zedira.com
To ensure full compatibility with robotic systems, DNase / RNase- and pyrogen-free PCR plates from Porvair Sciences feature high rigidity to minimise distortion before and after thermal cycling.
Produced in Class 10,000 clean room conditions – Porvair range of PCR plates are certified free of pyrogens as well as DNAse and RNAse enzyme activity enabling routine achievement of excellent PCR results. Porvair PCR plates are based upon a well design where the liquid meniscus comes below the plate surface eliminating sample carryover problems when using a plate lid.
Summarised in an easy-to-use selection guide (pages 14-15 of 2015 catalogue) the Porvair PCR plate range of standard or low profile 96-well PCR plates are available in specific optimised formats (full, half or no skirt), with well volumes of 100-200 microlitres. Designed for higher throughput assays, where samples are often at a premium, Porvair 384-well PCR plates offer a working well volume of only 30 microlitres. To ensure full compatibility with robotic systems the 384-well PCR plates offer a full plate skirt and high rigidity to minimise distortion before and after thermal cycling. Black alphanumeric printing on all PCR plates ensures easy well identification.
Available in bulk packs of 50 individually wrapped plates – Porvair Sciences 96-well and 384-well PCR plates reduce the cost of Polymerase Chain Reaction (PCR) analysis without compromising performance. For further information please contact Porvair Sciences on +44-1978-666240 or www.porvair-sciences.com
Established in 1992, Porvair Sciences Ltd. has developed internationally recognised expertise in microplate technology and manufacturing serving applications in Drug Discovery, Combinatorial Chemistry, Solid Phase Extraction, Protein Purification, High Throughput Screening, Environmental Analysis, Proteomics and Genomics. Porvair Sciences is a wholly owned subsidiary of Porvair plc.
———————
Worldwide HQ
Porvair Sciences Ltd
Clywedog Rd South
Wrexham Industrial Estate
Wales LL13 9XS
UK
Tel: +44 1978 666240
Web www.porvair-sciences.com
Gaithersburg, Maryland and SEOUL, Korea, February 17, 2015 - Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for its TOCE™-based herpes simplex virus (HSV) types 1 and 2 assay. This is the first product that Seegene has taken through the FDA, and it opens the way for Seegene’s other planned FDA submissions of multiplex real-time PCR reagents.
“This is an important milestone in support of our planned entry into the United States, the largest molecular diagnostic market in the world,” said Dr. Jong-Yoon Chun, Founder, CTO and CEO of Seegene. “After more than 10 years of extensive efforts to continually develop and commercialize novel technologies to surpass the capabilities of real-time PCR, we successfully invented MuDT™ technology, an ultimate multiplex real-time PCR technology that marks a new era in the molecular diagnostics industry. Through the US FDA approval, Seegene now intends to actively enhance its leadership in the multiplex real-time PCR diagnostic testing market.”
According to Seegene, the company aims to establish a new U.S. subsidiary in 2015 and seeks to further accelerate its growth in the rapidly evolving global molecular diagnostic market. Seegene will also continue to evolve its Allplex family of infectious disease panel tests for the U.S. market.
Allplex tests are based on its breakthrough MuDT™ technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis. Allplex tests are the most comprehensive and cost-effective multiplexed PCR molecular assays for infectious disease in the industry.
For example, Seegene’s CE-marked Allplex Respiratory Panel 1(Flu / RSV / FluA subtyping) simultaneously identify and quantify seven targets, including Influenza virus A and B, RSV type A and B, and Influenza A virus subtypes(H1, H3, and H1pdm09), making them the world’s first and only high-multiplexed respiratory panels based on real-time PCR platform.
About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies – ACP™, DPO™, READ™, TOCE™, mTOCE™ and MuDT™ – are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenomics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.com or call +301-762-9066.
Strong exhibitor line-up from over 15 countries and a comprehensive medical product, equipment & machinery showcase at Kenya’s biggest International Medical Trade Exhibition.
The increasing demand for medical manufacturing products, equipment, machinery, services and solutions has prompted a surge of representation at Africa’s premier medical exhibition, MEDEXPO AFRICA – KENYA 2015. Taking place at The Kenyatta International Conference Center, Nairobi , Kenya, from the 07 – 09 May, 2015, the exhibition profile innovative solutions from leading market players for the benefit of medical technology buyers from across the East African region. Targeted buyers from across the East Africa are seeking new products, equipment, machinery, services and solutions to keep abreast of industry trends and developments.
According to medical professionals in the region: “It will be the most important and relevant trade exhibition for industry professionals in the medical field to source for products, meet new business contacts, build partnerships, and keep abreast of industry trends and developments.” Kenya is currently the largest producer of pharmaceutical products in the Common Market for Eastern and Southern Africa (COMESA) region, supplying about 50% of the regions’ market. Out of the region’s estimated of 50 recognized pharmaceutical manufacturers; approximately 30 are based in Kenya.
Due to an aggressive campaign, the number of exhibitor’s registration has risen by at least 20% as compared to last year. Visitor inquiries & registration is very strong and a forecast in the increase in the visitors flow to a 25% rise for the event. MEDEXPO AFRICA – KENYA 2015 aims to raise the medical industry standards, by connecting market players such as manufacturers, suppliers, systems partners, researchers, engineers and technical buyers. Trade visitors from all over East & Central African countries are being invited directly and in collaboration with several regional trade bodies in Kenya, Tanzania, Ethiopia, Uganda, Somalia, Mozambique & Congo.
Every year, MEDEXPO attracts a huge number of radical medical equipment manufacturing & distribution companies to showcase their medical technologies, products and services. Both exhibitors & visitors receive the personalized attention in the show, hence making the MEDEXPO Africa eminent!
On behalf of GTCbio and the 2015 Advisory Board, you are invited the Epigenomics & Novel Therapeutic Targets Conference which takes place May 21-22, 2015 in Boston, MA. This meeting is part of The Pan-Omics Summit and focuses on transcriptional regulation, novel therapeutic targets and discoveries, pre-clinical to clinical drug development, new technological advances, and epigenomic biomarkers and diagnostics.
Epigenomics is still a growing field and young in comparison to its counterparts. Investigators are facing many challenges in terms of immunotherapeutic research and instrumental analysis. This conference is for the scientists, researchers, laboratory leaders, and managers who are working in the field and allows these experts to share their findings and techniques in order to bridge technological and computational gaps that affect datasets, interpretation, and the clinical applications of epigenomics.
Session topics include:
I. Transcriptional Regulation
II. Novel Therapeutic Targets and Discovery
III. Pre-Clinical to Clinical Drug Development
IV. New Technological Advances
V. Epigenomic Biomarkers and Diagnostics
VI. Neurological Disorders and Other Diseases
More Articles...
- 2nd Metabolomics – Advances & Applications in Human Disease Conference May 21-22, 2015, Boston, MA
- FMC 2015 – Frontiers in Medicinal Chemistry Antwerp, Belgium – September 14-16, 2015
- Lyophilisation & Freeze Drying USA on 29-30 April 2015, Iselin, New Jersey
- Pharmacovigilance, Drug Safety & Risk Management 11-12 May 2015, London UK
- Stem Cells in Drug Discovery 2015, 2-3 June 2015, Cambridge, UK
